Payment overview · 2025
General Payments
$530.20
27 reported records · 15 companies
Healthcare provider profile · identity verified
Jeffrey Clary, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SPARTANBURG, SC · NPI 1902872906
Verified facts
What the public records show
CMS Open Payments records show Jeffrey Clary, M.D. received $530.20 in general payments during 2025 across 27 reported records.
Dexcom, Inc. accounted for 17.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro, Nurtec Odt, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $92.17 | 17.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $71.81 | 13.5% | 5 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $70.54 | 13.3% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.66 | 9.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.44 | 6.5% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $30.43 | 5.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.24 | 5.5% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.64 | 5.2% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $23.07 | 4.3% | 1 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $20.78 | 3.9% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $18.78 | 3.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.43 | 3.3% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $14.38 | 2.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.19 | 2.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.64 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $530.20 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $92.17 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $71.81 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $71.81 | 5 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $70.54 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $51.66 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $51.66 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $30.43 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $29.24 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $27.64 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc. | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc. | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.19 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.64 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 84 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 132 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
84 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
132 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
87 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lorazepam | Lorazepam | 406 | 72 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 400 | 72 |
| Atorvastatin Calcium | Atorvastatin Calcium | 397 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 328 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 314 | 94 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 290 | 40 |
| Gabapentin | Gabapentin | 289 | 72 |
| Alprazolam | Alprazolam | 250 | 37 |
| Omeprazole | Omeprazole | 243 | 69 |
| Zolpidem Tartrate | Zolpidem Tartrate | 230 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 208 | 59 |
| Losartan Potassium | Losartan Potassium | 205 | 58 |
| Tramadol Hcl | Tramadol Hcl | 196 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 179 | 55 |
| Lisinopril | Lisinopril | 172 | 47 |
| Glimepiride | Glimepiride | 168 | 49 |
| Potassium Chloride | Potassium Chloride | 167 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 162 | 35 |
| Furosemide | Furosemide | 162 | 41 |
| Meloxicam | Meloxicam | 142 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 142 | 39 |
| Prednisone | Prednisone | 141 | 91 |
| Trazodone Hcl | Trazodone Hcl | 140 | 31 |
| Ozempic | Semaglutide | 132 | 21 |
| Clonazepam | Clonazepam | 127 | 24 |
| Famotidine | Famotidine | 126 | 36 |
| Farxiga | Dapagliflozin Propanediol | 124 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 124 | 36 |
| Azithromycin | Azithromycin | 116 | 94 |
| Simvastatin | Simvastatin | 116 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 114 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 37 |
| Metformin Hcl | Metformin Hcl | 107 | 31 |
| Diazepam | Diazepam | 105 | 19 |
| Carvedilol | Carvedilol | 98 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 96 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 90 | 26 |
| Eliquis | Apixaban | 87 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 86 | 25 |
| Mounjaro | Tirzepatide | 84 | 15 |
| Temazepam | Temazepam | 81 | 13 |
| Fenofibrate | Fenofibrate | 80 | 22 |
| Ondansetron Odt | Ondansetron | 78 | 34 |
| Buspirone Hcl | Buspirone Hcl | 75 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 20 |
| Montelukast Sodium | Montelukast Sodium | 67 | 19 |
| Testosterone Cypionate | Testosterone Cypionate | 67 | 11 |
| Bupropion Xl | Bupropion Hcl | 66 | 21 |
| Fluconazole | Fluconazole | 62 | 31 |
| Sertraline Hcl | Sertraline Hcl | 62 | 17 |
| Atenolol | Atenolol | 61 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 56 | 19 |
| Valsartan | Valsartan | 56 | 18 |
| Memantine Hcl | Memantine Hcl | 55 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 16 |
| Pregabalin | Pregabalin | 54 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 51 | 14 |
| Synthroid | Levothyroxine Sodium | 51 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 36 |
| Estradiol | Estradiol | 48 | 13 |
| Spironolactone | Spironolactone | 48 | 18 |
| Valacyclovir | Valacyclovir Hcl | 48 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 48 | 12 |
| Allopurinol | Allopurinol | 47 | 12 |
| Glipizide | Glipizide | 47 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 46 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 46 | 14 |
| Methocarbamol | Methocarbamol | 46 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 46 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 45 | suppressed |
| Jardiance | Empagliflozin | 44 | suppressed |
| Repatha Sureclick | Evolocumab | 44 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 42 | suppressed |
| Trulicity | Dulaglutide | 41 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 34 |
| Clonidine Hcl | Clonidine Hcl | 40 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | 12 |
| Ezetimibe | Ezetimibe | 40 | 14 |
| Januvia | Sitagliptin Phosphate | 39 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 38 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 38 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 37 | 14 |
| Levofloxacin | Levofloxacin | 37 | 34 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 34 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Celecoxib | Celecoxib | 33 | 11 |
| Donepezil Hcl | Donepezil Hcl | 33 | 12 |
| Promethazine Hcl | Promethazine Hcl | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | 11 |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Mupirocin | Mupirocin | 30 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 21 |
| Finasteride | Finasteride | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | 11 |
| Bumetanide | Bumetanide | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Cefdinir | Cefdinir | 24 | 19 |
| Testosterone | Testosterone | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 23 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 19 |
| Baclofen | Baclofen | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Indomethacin | Indomethacin | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 21 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 20 | suppressed |
| Desloratadine | Desloratadine | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Nystatin | Nystatin | 20 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 15 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Modafinil | Modafinil | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Corlanor | Ivabradine Hcl | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Livalo | Pitavastatin Calcium | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $530.20 · 27 records | Dexcom, Inc. | CREON, CT THROMBECTOMY SYSTEM KIT, Dexcom G6 Transmitter, FLOWTRIEVER CATHETER, S, INJECTAFER, LINZESS, Leqembi, MOUNJARO, NEFFY, NEXLETOL, NURTEC ODT, ONPATTRO, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, Tymlos, UBRELVY, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error